Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

NCT01061515 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma

Interventions

DRUG: Intraperitoneal Oxaliplatin
DRUG: Bevacizumab
DRUG: Capecitabine

Sponsor

Washington University School of Medicine